Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines.
Our previous study showed that human peritoneal conditioned medium (CM) increased the matrix metalloproteinase-9 (MMP-9) secretion and invasiveness of ovarian cancer cells (NOM1). In an effort to identify this MMP-9-stimulating factor, we examined the effects of extracellular matrix components, such as type IV collagen, laminin, and fibronectin, on ovarian cancer cells. We found that fibronectin increased the MMP-9 activity of NOM1 cell CM in a concentration-dependent manner and that the peritoneal CM contained high level of fibronectin. An increase of MMP-9 activity in NOM1 cell CM by the peritoneal CM was almost completely blocked by 20 microg/ml of anti-integrin alpha5/FnR antibody and RGD polypeptides. Furthermore, after immunoprecipitation by antifibronectin antibody supernatant of the peritoneal CM did not increase MMP-9 activity in NOM1 cells. Fibronectin and the peritoneal CM also increased MMP-9 activity and expression in NOM1 cell lysate, and these effects were blocked by anti-integrin alpha5/FnR antibody. Invasiveness of NOM1 cells was enhanced by fibronectin and the peritoneal CM in a concentration-dependent manner, and anti-integrin alpha5/FnR antibody blocked these effects. These results suggested that fibronectin secreted from peritoneum increased MMP-9 activity and expression, and, in turn, invasiveness of ovarian cancer cells.
Shibata
K
K
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
Kikkawa
F
F
Nawa
A
A
Suganuma
N
N
Hamaguchi
M
M
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000276:immunology / Q000502:physiology; D017364:Collagenases / Q000096:biosynthesis*; D017077:Culture Media, Conditioned; D003536:Cystadenocarcinoma / Q000201:enzymology / Q000473:pathology; D004790:Enzyme Induction; D005260:Female; D005353:Fibronectins / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D039482:Integrin alpha5; D007700:Kinetics; D020780:Matrix Metalloproteinase 9; D008970:Molecular Weight; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000473:pathology*; D010537:Peritoneum / Q000166:cytology / Q000473:pathology / Q000502:physiology*; D017469:Receptors, Fibronectin / Q000276:immunology / Q000502:physiology; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D017077:Culture Media, Conditioned; D005353:Fibronectins; D039482:Integrin alpha5; D017469:Receptors, Fibronectin; D017364:Collagenases; D020780:Matrix Metalloproteinase 9